Shield Therapeutics (LON:STX) Presenting at the Proactive One2One Virtual Forum 8th April 2021
Shield is a de-risked commercial stage, pharmaceutical company focused on addressing iron deficiency in adults with or without anaemia. Our clear purpose is to develop products that help patients become people again, enabling them to enjoy the things that make a difference in their everyday lives. Our lead product Feraccru®/Accrufer® is a novel, stable, non-salt based oral therapy and is approved in the United States, European Union, UK and Switzerland for the treatment of iron deficiency with or without anaemia in adults. In Europe the product is marketed as Feraccru® with commercialisation led by Norgine BV. In the USA the product will be marketed as Accrufer®. We are currently in the process of selecting a partner for the US market. We also have an exclusive licence agreement with ASK Pharm who will lead development and commercialisation in China, Hong Kong, Macau and Taiwan.